You are here
P&T September 2015
The Food and Drug Administration hopes to close gaps in laws related to repackaging of pharmaceuticals or biologics by hospital pharmacies and bulk compounding facilities.
This article explores the basis of glucose-6-phosphate dehydrogenase deficiency and defines the role that health care informatics can play in optimal treatment.
Opioid-use monitoring, medication-error prevention, and counseling/duty-to-warn issues illustrate new or emerging legal risks for pharmacists as their roles expand.
With disease-modifying treatments available for relapsing–remitting multiple sclerosis (MS), the quest for therapies for progressive MS has become a key focus of research.
This second of five articles reviews Parkinson’s disease pharmacotherapy, focusing on dopaminergic agents such as levodopa/carbidopa and dopamine receptor agonists.
We review sessions on metastatic colorectal cancer and hepatocellular carcinoma.
Agents are approved to treat exacerbations and symptoms and as disease-modifying therapy. Most therapies in the works would address relapsing forms of the disease.
An ISMP survey finds problems involving proper use of Carpuject prefilled syringes.
The Centers for Medicare and Medicaid Service’s final ACO rule offers little for pharmacists.
FDA approvals, drug indications, and updates
Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations